Gain Therapeutics Inc. held its annual meeting of stockholders on June 24, 2025. The election of eight directors was approved. The appointment of Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to increase the authorized shares of common stock from 50,000,000 to 100,000,000 was approved. The proposal to adjourn the meeting to a later date, if necessary, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.